Appropriate treatment for prostate cancer is controversial because of the lack of information from randomized clinical trials indicating the bene®ts of one treatment over another. Watchful waiting or conservative management remains an alternative for this disease. This paper assesses the extent to which White and Black prostate cancer patients in the USA choose nonaggressive therapy. Nonaggressive therapy is de®ned as patients not receiving cancer-directed surgery or radiation, or that undergo a transurethral resection of the prostate (TURP)/simple prostatectomy but no radiation. Of 112,445 prostate cancer patients diagnosed in 1992 ± 1996, 40% Whites and 46% Blacks were not aggressively treated. Approximately 28% Whites and 33% Blacks did not receive cancer-directed surgery or radiation, and 12% Whites and 13% Blacks underwent a TURP/simple prostatectomy but no radiation. Stage, histologic grade and age at diagnosis, race (White and Black), and number of cancer primaries each signi®cantly in¯uence how patients are managed. Black patients are more likely than White patients to forego aggressive therapy, even after adjusting for less preferential stage and histologic grade at diagnosis, as well as differences in age and number of cancer primaries. Explanations for this result deserve further consideration. Prostate Cancer and Prostatic Diseases (2000) 3, 94±99.
Introduction
Choosing an appropriate method for treating prostate cancer is controversial, partly because of lack of information from randomized clinical trials documenting the net bene®t of one treatment option over another. Treatment options range from watchful waiting to aggressive therapy. 1 Because of the high risk of morbidity and the possibility of mortality associated with aggressive treatment involving radical prostatectomy or radiation, 2 ± 6 the decision to forego therapy is further complicated. Aggressive therapy is usually reserved for patients in good health, with a life expectancy greater than 10 ± 15 y, with their tumor con®ned to the prostate gland, with a negative bone scan, and who elect this intervention. 7 ± 10 However, watchful waiting has been proposed as a viable alternative, even for some men with localized, low-grade prostate cancer. 11 ± 17 The purpose of this paper is to evaluate the extent that White and Black prostate cancer patients in the USA choose nonaggressive therapy. The evaluation considers stage, age and histologic grade at diagnosis, as well as whether one or more cancer primaries involving other sites are present. Also considered are reasons why patients do not receive cancer-directed surgery or radiation, such as it is not recommended or it is refused. Angeles), representing about 14% of the US population. The SEER program comprehensively tracks cancer incidence and survival in the USA. It collects and reports information on tumor characteristics (for example, stage and histologic grade at diagnosis), patient characteristics (for example age and race), whether single or multiple cancer primaries are present, length of follow-up, date and cause of death, and ®rst course of cancer-directed therapy. 18 Cancer characteristics and treatment information are obtained from hospital records, clinical and nursing home records, private pathology laboratories and radiotherapy units, and death certi®cates.
This study considers clinically or pathologically determined stage and histologic grade. These are useful descriptors of the biological potential of prostate cancer. The four terms used to describe disease stage are: localized (an invasive neoplasm con®ned to the prostate capsule), regional (a neoplasm that has extended beyond the limits of the organ or origin directly into surrounding organs or tissues, into regional lymph nodes, or both), distant (a neoplasm that has spread to parts of the body remote from the primary tumor), and unstaged (a neoplasm for which there is not suf®cient information to assign a stage). Histologic grade has three categories, based on the degree of cellular differentiation: well differentiated (Gleason 2 ± 4), moderately differentiated (5 ± 7), and poorly differentiated or undifferentiated (8 ± 10). Tumors not classi®ed by pathologists are de®ned as unknown grade. SEER uses best available data from clinical and pathology reports for staging disease. Surgically treated prostate cancer patients often have their diagnosis pathologically upstaged from local to regional disease or upgraded from well differentiated to moderately differentiated as a result of radical prostatectomy. 7, 22 Hence, localized and regionally staged cases are combined. Also combined are well differentiated and moderately differentiated tumors. 19 Nonaggressively treated patients are de®ned as those that do not undergo radical prostatectomy (and about 3% other surgery, such as exenteration) or radiation. We do not consider transurethral resection of the prostate (TURP) or simple prostatectomy as aggressive therapy, given they are primarily performed in older patients as palliative intervention. 20, 21 This surgery is also common among men with benign prostate hyperplasia, and occasionally results in a prostate cancer diagnosis. 20 On the other hand, radical prostatectomy and radiation are typically performed with curative intent. 7 ± 10 For 201 (0.20%) White and 23 (0.16%) Black patients it was unknown whether surgery was performed; and for 189 (0.19%) White and 46 (0.33%) Black patients it was unknown whether radiation was received. These unknown cases were included in the nonaggressively treated group.
Incidence rates are derived by dividing the annual number of new cases of prostate cancer diagnosed in the geographic regions of the SEER Program by the midyear population for these regions. Population values come from the United States Bureau of the Census. 23 Rates are age-adjusted to the 1970 United States standard population to control for changes in the population agedistribution over time and to allow for meaningful comparisons of the rates. The chi-square test is used to evaluate independence between select variables. 24 In addition, logistic regression models are employed to assess potential differences between White and Black cases with respect to aggressive therapy. These models are adjusted for stage, age and histologic grade at diagnosis, and whether or not one or more cancer primaries involving other sites are present.
Results
Age-adjusted invasive prostate cancer incidence rates in White and Black men are shown in Table 1 . The rates decline over the calendar year, with the exception of 1992 ± 1993 for Blacks. For the combined years 1992 ± 1996, the rate in Blacks was 1.6 times that of Whites. Figure 1 shows percentages of White and Black prostate cancer patients not aggressively treated by calendar year. Those not receiving aggressive therapy were further categorized into two groups, those not undergoing cancer-directed surgery or radiation, and those having a TURP/simple prostatectomy but no radiation. Over the study period, 39.9% Whites and 46.0% Blacks were not aggressively treated. Approximately 27.8% Whites and 33.4% Blacks did not receive cancer-directed surgery or radiation, and 12.1% Whites and 12.6% Blacks underwent a TURP/simple prostatectomy but no radiation. For both Whites and Blacks, the percentages of patients not receiving cancer-directed surgery or radiation increased, leveled off, and then decreased. For patients treated with TURP/ simple prostatectomy but no radiation, the percentages consistently decreased over the calendar years represented. Blacks were consistently less likely to be aggressively treated.
Age-speci®c percentages of invasive prostate cancer patients not undergoing aggressive treatment are shown in Figure 2a (race), b (histologic grade), c (stage), and d (number of cancer primaries). In general, the percentages slightly decrease, level off, and then increase over the age span. In Figure 2a , the percentages of patients not aggressively treated are consistently higher for Blacks, although the difference becomes small by 80 y and older. In Figure  2b , percentages not aggressively treated were similar, particularly by ages 60 and older, between well/moderately differentiated cases and poorly differentiated/ undifferentiated cases. For those with unknown grade, percentages were generally considerably higher, more so in younger ages. Figure 2c shows the pronounced effect of stage at diagnosis on receipt of therapy. Patterns in percentages for patients not aggressively treated across the age span are similar between local/regional and unstaged groups, albeit considerably lower for local/ regional patients. Age has relatively little in¯uence on whether treatment is received for distant staged patients. Figure 2d shows that percentages not aggressively treated tend to increase with age in similar fashion for both patients with a single primary and those with one or more cancers involving other sites. The percentages are higher for those with multiple cancer primaries in ages 45 ± 79, but similar in ages 80 and older.
Logistic regression is used to assess whether Black patients are less likely than White patients to undergo aggressive therapy after adjusting for selected characteristics (stage, histologic grade and age at diagnosis, and number of cancer primaries). The likelihood of nonaggressive therapy for Black compared to White patients is signi®cant and only increases by adjusting for the selected variables. The odds ratio is 1.31 (95% CI: 1.26 ± 1.36) in the unadjusted model and 1.33 (95% CI: 1.27 ± 1.39) in the adjusted model. In the adjusted model, each of the selected variables signi®cantly contributes (P`0.01) to the ®t of the model.
The SEER program collects information on why certain patients did not receive cancer-directed surgery. Table 2 shows these reasons for the study subjects. The distribution of responses was signi®cantly different between racial groups. A larger proportion of Blacks failed to receive cancer-directed surgery because it was`not recommended' or they`refused' it. On the other hand, a larger proportion of Whites had an`unknown reason' given for not undergoing surgery. Unfortunately, the radiation variable in SEER does not provide reasons why radiation was not selected, except for refusal. Compared to the number refusing cancer-directed surgery, refusal was much less commonly given as a reason for not receiving radiation. There were 0.6% Whites and 1.2% Blacks that refused radiation.
Discussion
Prostate cancer incidence rates began to fall in 1993 for Whites and 1994 for Blacks. 25, 26 The decreasing rates follow the same pattern as in ®rst-time prostate-speci®c antigen rates for both races. 27 Previous reports have shown the decrease to occur in all stage, histologic grade, and age categories. 28 In this context, the paper identi®es the extent of nonaggressive therapy according to calendar year and age in White and Black invasive prostate cancer patients.
A number of articles appearing in the early 1990's discussed watchful waiting as a viable option for managing prostate cancer. 11 ± 17 These studies may have in¯u-enced the increasing percentages of Whites and Blacks not receiving cancer-directed surgery or radiation over 1992 ± 1995. On the other hand, the decrease in percentages observed in 1996 may represent a shift toward greater con®dence in aggressive therapy, as particularly seen among Whites. A recent study has suggested that aggressive therapy may be responsible, at least in part, for decreasing prostate cancer mortality observed since the early 1990s. 29 
Figure 2
Percentage of invasive prostate cancer patients not receiving aggressive therpay by age at diagnosis and select characterisitcs. The percentage of patients undergoing aggressive therapy decreased with age, most appreciably in those aged 70 y and older. Nevertheless, about 20% of patients aged 80 ± 84 and 5% of patients aged 85 and older received aggressive therapy. Radiation explained almost all of this treatment, with the percentage of men 80 ± 84 treated with radical prostatectomy 2% for Whites and 1% for Blacks. The percentages are near zero for ages 85 and older. 30 Some of the radiation therapy received in these older ages may be for palliation. 31 Blacks, distant staged, unstaged, those with unknown grade, and those with one or more cancer primaries involving other sites than prostate cancer tended to be most likely not to receive aggressive therapy.
Several studies have shown that Blacks tend to report with later stages of cancer and with poorer differentiated tumors. 28, 32 Indeed, in this study 5.9% of Whites and 9.5% of Blacks were diagnosed with distant stage disease; 11.4% of Whites and 13.8% of Blacks with unstaged disease; and 8.2% of Whites and 10.7% of Blacks had unknown tumor grade. The extent that differences in stage, histologic grade and other prognostic factors in¯u-ence higher percentages of nonaggressive therapy observed in Blacks vs Whites is explored using logistic regression models adjusting for stage, histologic grade and age at diagnosis, and whether or not one or more cancer primaries involving other sites are present. However, the models show that, even after adjusting for these variables, Blacks continued to be less likely to receive aggressive therapy.
In the USA, improvements in medications as an alternative for treating urinary complications led TURP rates to begin falling after 1987. 20, 33 Given that TURP is much more common than simple prostatectomy, almost 18 times (15, 263 TURPs to 855 simple prostatectomies) in our data, falling percentages of Whites and Blacks treated with a TURP/simple prostatectomy but no radiation is primarily explained by falling TURP rates. Percentages treated with TURP/simple prostatectomy but no radiation may have declined more rapidly in Blacks than Whites if Blacks accepted new medication alternatives more quickly.
It is possible that some of the TURP/simple prostatectomy but no radiation group may have had their prostate cancer diagnosed as a result of the surgery. 20 These surgeries are often performed in response to health problems, such as benign prostate hyperplasia. Hence, to say that they received conservative therapy for prostate cancer is not entirely correct. Although the reported proportion of TURP/simple prostatectomy is similar between Whites and Blacks, it is impossible to know from the SEER data whether Blacks were more or less likely to undergo a TURP/simple prostatectomy because of a prostate cancer diagnosis. Nevertheless, the paper provides an indication of the proportion of patients that underwent TURP/simple prostatectomy for prostaterelated complications but did not undergo radiation or more aggressive surgery.
SEER actively follows diagnosed cases and obtains cancer and treatment information through several sources, as mentioned above under the description of the SEER program. In the analysis, patients with unknown surgery or radiation were included with those not receiving cancer-directed surgery or radiation, respectively. Bias would result if the proportion in thè unknown' category substantially differed between Whites and Blacks. However, very small numbers of both White and Black patients with`unknown' surgery or radiation relative to the overall study population, as listed in the methods above, indicates that this is not a problem.
It is possible that fewer Black patients opted for aggressive treatment because of a higher prevalence of comorbid disease. Unfortunately, SEER data does not include comorbid conditions other than cancer, but we did adjust for the occurrence of one or more cancer primaries involving other sites than prostate cancer. We would expect the likelihood of comorbid disease to increase with age. Yet, Black patients in the study actually had a signi®cantly younger age distribution than White patients (Chi-square 640.3, P`0.001).
The results show that reasons why cancer-directed surgery was not performed differed between White and Black prostate cancer patients. Unknown reasons were given as to why cancer-directed surgery was not received more often in Whites (34%) than Blacks (21%). These high percentages make it dif®cult to interpret whether there is a real difference between Whites and Blacks in the other reasons given, such as not recommended or refused. Nevertheless, poorer stage and grade at diagnosis among Blacks is consistent with the difference observed in`not recommended'. In addition, it was noted above that aggressive therapy decreases with age, most appreciably in those aged 70 y and older. It was also stated that a larger proportion of White vs Black patients were in the older age groups. This may help explain the higher percentage of Whites not receiving cancer-directed surgery for unknown reasons; that is, they did not refuse recommended surgery, but chose not to receive it because of their age.
Although we adjusted for several prognostic indicators previously shown to in¯uence treatment choice and mortality, we were unable to adjust for all potential confounding factors. Nonaggressive management may have been in¯uenced by other factors such as socioeconomic status or education.
Conclusion
SEER data allows us to better understand why men diagnosed with invasive prostate cancer do not receive aggressive therapy. Stage, histologic grade and age at diagnosis, race (White and Black), and number of cancer primaries each directly in¯uence whether patients are not aggressively managed. Black patients were less likely than White patients to receive aggressive therapy, even after adjusting for less preferential stage and histologic grade at diagnosis, as well as differences in age and number of cancer primaries. Reasons for not receiving cancer-directed surgery differ between Whites and Blacks. Study of these differences deserves further consideration.
